by Kyle LaHucik |
The conditional approval of Biogen’s Aduhelm (aducanumab) might have been controversial, but the FDA’s decision on Monday could spur a renaissance of sorts for the Alzheimer’s space after a “decade of a big hole.”
“Literally the floodgates have opened for funding,” said Alzheon CEO Martin Tolar, Ph.D., in an interview following the landmark regulatory decision.
Tolar knows from experience how difficult it has been to attract financing in the past decade as his company, which dosed its first patient in a phase 3 study of an oral anti-amyloid treatment last week, has twice pulled an initial public (IPO) offering due to timid investors.
Read the full article here